![](https://pharmashots.com/public/default-image/default-730x400.png )
Novartis Expands its Cell Therapy Collaboration with Intellia Therapeutics for CRISPR/Cas9-Based Therapy
Shots:
- Intellia to receive $10M upfront- milestones and royalties on sales. Novartis to get rights to Intellia’s CRISPR/Cas9 technology for the development of ex-vivo cell therapy using ocular stem cells
- Under the extension of previous agreement with Novartis- Intellia to get the rights of Novartis’ lipid nanoparticle (LNP) technology for development of genome editing in ex-vivo & in-vivo
- Intellia’s CRISPR/Cas9 technology enables editing of disease-associated genes- providing improved cell therapies for cancer and immunological diseases
Ref : Intellia Therapeutics | Image: Greek Reporter
Tags
![](https://pharmashots.com/public/images/Senior-2023-08-17-64ddc3af74ec4.png)
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com